Science thomsonreuters.com

Victor Camlek is the director of Market Intelligence and Market Research. In this role Victor is responsible for monitoring, assessing, alerting and advising senior management about the issues, impacts and opportunities affecting all our scientific markets.

With over 25 years experience in the industry, Victor has led market intelligence teams and served as a principal market intelligence analyst focused on the telecommunications industry for Telcordia Technologies.  He led a team of senior market intelligence analysts who provided information based consulting services for the telecommunications carriers and internal clients.  Prior to his 17 years at Telcordia, Victor worked as an information professional in the healthcare and engineering industries.

Currently Network Chair for the SLA CI Division responsible for implementing a mentoring program, Victor is also a candidate for the Chair Elect for the Division and has written a number of articles published in the Bulletin of the SLA Competitive Intelligence Division. In addition he is a member of the NFAIS 2009 conference planning committee.

Victor has a Masters in Library Science from Queens College of the City University of New York and a BA in communications from Hunter College of the City University of NY.

Presentations & Conferences

• The Making of A CI Professional: The SLA Division Competitive Intelligence Mentoring Program | SLA Annual Conference | Seattle, June 2008
• The New Information Economy: The Changing Landscape | NFAIS Annual Conference | Philadelphia, February 2008
• Collaboration and Productivity Tools: A Survey of Knowledge Workers | Online | London, December 2007
• Competitive Intelligence in the Age of Google | Online | London, December 2006
• Market Research: Anticipating and Monitoring User Needs | SLA Annual Conference | Toronto, June 2005

In his current role Mark Markley supports the intellectual property portfolio including Aureka, MicroPatent, and Thomson Innovation. He focuses on increasing the visibility of patent solutions and supporting the current subscriber base.

He has been involved in patent information for over 14 years and is a member of PIUG.

Following graduate school in microbiology and molecular biology Mark worked for patent law firms in Washington DC. He joined Thomson Reuters with the acquisition of Derwent and has held various training and sales roles. He has also worked for STN/Fiz-Karlsruhe as regional sales manager and at LexisNexis as an intellectual property specialist.

Product Expertise

• Aureka
• Thomson Innovation
• Thomson Data Analyzer

Presentations & Conferences

• Thomson Innovation | ACS Spring Conference | New Orleans, April 2008

Donald Walter joined the company over 15 years ago. His primary responsibility is to train users on our scientific and healthcare solutions, specializing in chemical and patent information. He also conducts searches and analyses for legal and industrial clients, with a special emphasis on pharmaceutical and chemical subjects.

He learned his craft at Exxon Research and Engineering, conducting patent and scientific literature searching for clients in the legal and technical departments.

With over 28 years experience in the patent industry and a Ph.D. in Chemistry from Yale, Don is a member of the Patent Information User Group and the American Chemical Society.

Product Expertise

• GENESEQ
• DWPI
• Thomson Innovation
• Thomson Pharma
• Web of Knowledge/Web of Science

Presentations & Conferences

• Are There Hallmarks of Important Patents? | Patent Information Expo 2008 | November 11-12, 2008

Bob Stembridge has 25 years experience working within the patent information industry and in his current role is responsible for liaison with customer user groups on behalf of the organization.

He is currently Chair of Patent and Trade Mark Group and has published articles on research and innovation process, patent analysis, patent portfolio management and IPC reform. Bob is also an affiliate member of the Chartered Institute of Library and Information Professionals and a full member of the American Chemical Society. He presents regularly at information conferences and events.

Bob graduated from University of Sussex with a BSc in Chemistry. He joined Thomson Scientific in 1980 and has held various roles in editorial, marketing, sales and product development. Leaving in 1988 for interludes working as Information Analyst specialising in patent analytics at British Petroleum and uropean Sales Liaison with Dialog, he returned to Thomson Reuters in 1996.

Presentations & Conferences

• Thomson Innovation – The New Standard in IP Research and Analysis | IPI-ConfEx - Barcelona, March 2008 | PIUG - Arlington, May 2008 | SLA - Seattle, June 2008
• Never Mind the Quality, Feel the Width | EPO Information Conference | Stockholm, October 2008

Rob Willows is Vice President, Patent Offices and Special Accounts. He manages business relationships with Patent and Trademark Offices worldwide, with a special focus on delivering customized patent information solutions that enhance the processes of prior art search and examination within these offices.

Rob has been responsible for successful in-house loads of our data, including the World Patents Index database, at EPO, USPTO, JPO and the Chinese Patent Office. He meets regularly with senior officials of all the major patent offices for strategic discussions on key issues relating to Intellectual Property.

With over 35 years experience in the field of patent and Scitech information, Rob is a regular speaker at major international IP conferences, including EPIDOS and EAPIC. He is also a member of the Coalition for Patent and Trademark Information Dissemination and PatCom (The Patent Committee).

Product Expertise

• GENESEQ
• DWPI
• Thomson Innovation

Presentations & Conferences

• Using IP Information to Enhance Business Returns and Shareholder Value | Intellectual Property Strategy Forum 2.0 | Syndey, February 2008

Shannon Bennett is a member of the Thomson Reuters API Intelligence team. In addition to collecting and validating intelligence contained in the Newport product suite, she is following closely developments in the Indian API and finished dose markets and has written and presented on that topic.

Prior to joining Thomson Reuters in 2009, Shannon was the Regulatory Affairs and Marketing Coordinator at Putney, Inc., a specialty veterinary drug company. Shannon holds a degree in journalism from University of New Hampshire.

Publications, Presentations & Conferences

• Examining India's Focus on APIs & Increasing Opportunities | API Global Sourcing Strategies | Berlin, June 2010
• The Rise of India | Chemistry Today | May 2010

Andrew F Bourgoin is a Pharmaceutical Research Analyst at Thomson Reuters. In addition to collecting and validating the intelligence contained in the Newport product suite, Andrew actively tracks developments within the global biologic pharmaceutical landscape. Prior to joining Thomson Reuters, Andrew was a graduate student at the Muskie School for Public Service where he received a master degree in public policy and management.

Publications, Presentations & Conferences

• Competition Heats Up in the Biologics Market | Pharma Magazine | July/August 2011
• What You Need to Know About the Follow-On Biologics Marketing in the U.S.: Implications, Strategies and Impact PDF | Thomson Reuters White Paper | January 2011
• The US Follow-on Biologic Market- Developments, Trends and Strategies PDF | Thomson Reuters Webinar | February 2010

In her current position as Manager of Small Molecule Research at Thomson Reuters, Molly is responsible for overseeing the collection and validation of small molecule intelligence contained in the Newport product suite. Newport's research team specializes in gathering competitive intelligence on the worldwide active ingredients market and generic pharmaceutical sector.

Prior to joining Thomson Reuters in 2007, Molly worked in the environmental field as a project coordinator and quality assurance officer. She holds a degree in chemistry from Smith College, and performed graduate studies at the State University of New York School of Environmental Science and Forestry.

Publications, Presentations & Conferences

• Current & Future Sourcing Trends: Is India and China the only future for API sourcing? PDF | CPhI Worldwide | Frankfurt, October 2011
• API Sourcing in China and India: Is Asia the Only Option for the Future? PDF | CHEManager Europe | October 2011
• Active Ingredient Sourcing Trends: analyzing the shift from traditional sourcing markets and their potential resurgence PDF | Chemistry Today | July/August 2011
• Interview with Mike Rice: Russia intends to make the drugs that it needs PDF | Generics Bulletin | April 8, 2011
• Russia: Effects of government involvement in creating pharma strategy PDF | PharmaSource | Berlin, March 24, 2011
• Geo-Sourcing Trends 2011: Analysing the latest sourcing trends and pharmerging markets PDF | PharmaSource | Berlin, March 23, 2011

Benjamin Burck is responsible for the Paragraph IV patent challenge coverage that appears in Thomson Reuters Newport products. Ben joined Thomson Reuters in 2005 as an analyst on the Newport API intelligence team, gathering and validating competitive intelligence on the worldwide active ingredients market.

Before joining Newport, Ben spent eight years documenting diagnostics devices and laboratory automation for Bayer HealthCare. He previously had a career as a research and academic librarian, first at the Research Libraries of the New York Public Library and later at the University of Pennsylvania. Ben has a BA from Northwestern University and a Master's degree from Indiana University.

Publications, Presentations & Conferences

• Preparing for Paragraph IV Patent Challenges PDF | Webinar | February 2011
• Paragraph IV Watch (series produced in collaboration with the editors of Generics Bulletin)
  • Desonate disclosure could prove costly PDF | Generics Bulletin | 10 June 2011
  • Dexilant depicts drama of US first-to-file PDF | Generics Bulletin | 6 May 2011
  • Lotronex challenge raises timing issues PDF | Generics Bulletin | 4 March 2011
  • Firms are awake to Silenor opportunity PDF | Generics Bulletin | 1 February 2011
  • Zydus tries novel strategy on Strattera PDF | Generics Bulletin | 3 December 2010
  • Challengers eye bimatoprost patents PDF | Generics Bulletin | 15 October 2010
  • Ezetimibe attracts additional interest PDF | Generics Bulletin | 17 September 2010
  • Companies pick their paths on Trilipix PDF | Generics Bulletin | 16 July 2010
  • Filings for Vanos rivals remain topical PDF | Generics Bulletin | 30 June 2010
  • Intuniv shows the value of exclusivity PDF | Generics Bulletin | 28 May 2010
  • Sandoz aims to call the tune on Lyrica PDF | Generics Bulletin | 23 April 2010
  • Paddock and Perrigo pursue Clobex PDF | Generics Bulletin | 26 March 2010

Mike Chace-Ortiz is responsible for managing the long-term development of our products and services for generic companies and innovators. He joined Thomson Reuters (then Newport Strategies) in 2003 and has held a number of roles within the company including leading the Custom Solutions Team, product specialist and new business development Director.

With 15 years in life sciences, Mike has experience of the generic pharmaceuticals industry, APIs, innovator discovery, research, pre-clinical and clinical development, regulatory and commercial processes as well as pharmaceutical information systems. Previously, Mike was a Managing Consultant with PA Consulting Group’s Life Science & Technology practice in Cambridge, MA. He has also held management positions in the Life Science practices of Barnett International/PAREXEL and with Deloitte Consulting in Philadelphia, and Bath, UK.

He obtained a Master of Engineering in Electronics, is a member of the Institute of Electrical Engineers, a Chartered Engineer and in 1985 received the Telecom Equipment Manufacturer’s Association (TEMA) Award for Excellence in R&D.

Product Expertise

• Generic Intelligence & Newport

Presentations & Conferences

• Second Wave of Emerging Markets PDF | PHARMASOURCE | Munchen, March 2010
• Deals Megatrends Part II PDF | PHARMASOURCE | Munchen, March 2010
• The Future of Deals in the Generic Industry PDF | DCAT | New York, March 2010
• Pharma Sourcing from India and China PDF | PHARMASOURCE | Berlin, March 2009
• Blurring of the Lines: Is Innovator and Generic Becoming Harder to Discern? PDF | DCAT | New York, March 2008
• The Role of API Intelligence in Generic Product Development | CPhI China | Shanghai, June 2007
• Tools and Trends for Generic Product Selection | CPhI Japan | Tokyo, April 2007
• Generic Business Development Tools | CPhI Worldwide | Paris | November 2006
• API: The Secret Ingredient in Specialty Portfolios | CBI Specialty Pharmaceutical Conference | Philadelphia, 2003
  

David Harding joined Thomson Reuters in 2005 as a member of Newport’s research team which specializes in gathering competitive intelligence on the worldwide active ingredients market and the generic pharmaceutical sector.

In 2007, Dave took an additional role, travelling worldwide, to support the Thomson Reuters global sales force, with the sales of Newport Vision and Newport Horizon. He received recognition for this work with the Thomson Scientific Outstanding Contribution to Business Award.

Prior to joining the company Dave worked in the legal field conducting patent search and analysis. He obtained a BS in Economics with Business minor from the University of Utah.

Product Expertise

• Generic Intelligence & Newport

Presentations & Conferences

• How M&A Activity is Shaping the Future of the Industry and Your Business PDF | DCAT | New York, March 2010
• How Originators Can Improve Their Understanding of Generic Competition PDF | CPhI Spain | Madrid, October 2009
• Identifying And Exploiting API Opportunities Across Emerging Markets | Berlin, Germany , November 2008
• Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success | CPhI China, Shanghai | June 2008
• Perceptions vs. Reality, Facts and Figures on the Generic Industry | DCAT Week - New York, March 2008 | CPA Event - Italy, May 2008
• Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment | KDRA event, South Korea | June 2007

Bob Kennedy is the Manager of Industry Research and is responsible for overseeing the activities of the Thomson Reuters API Intelligence team who collect and validate the competitive API intelligence that is contained in the Newport product suite.

Prior to joining Thomson in 2007, Bob was a QA consultant for Synta Pharmaceuticals. He also held roles as both a scientist and a QA auditor during his six year term at XenoTech LLC, a company specializing in non-clinical drug metabolism and drug-drug interaction studies. Bob holds a master’s degree in biology from Western Illinois University.

Product Expertise

• Generic Intelligence & Newport
• GDUFA: Who Will Benefit? - Published in CHEManager Europe No.1-2/2012

Presentations & Conferences

• Current & Future Sourcing Trends: Is India and China the only future for API sourcing? PDF | CPhI Worldwide | Frankfurt, October 2011
• China takes action on image PDF | Specialty Chemicals Magazine | August 2011
• Survival of the Fittest PDF | Specialty Chemicals Magazine | June 2010
• Can China Retain its API Sourcing Appeal? PDF | Scrip 100 | December 2009
• For How Long Will the Chinese API Sourcing Market Retain Its Appeal? PDF | API Global Sourcing Strategies | Berlin, June 2009
• China’s Changing Role in the Global Pharmaceutical Supply Chain | Scrip Online | January 29, 2009

As the Director of Generics and API Intelligence, Kate Kuhrt oversees Thomson Reuters research efforts regarding the generic and active ingredient industries. Kate joined us with the acquisition of Newport Strategies in 2004. Kate has played an integral role in expanding the worldwide network of industry experts with whom the API intelligence team works to gather and validate the accuracy of data about APIs and their manufacturers. She has published a number of articles discussing the challenges and opportunities for the generics industry in different parts of the world

Prior to joining Newport Strategies in 2002, Kate was an Associate at the Pharmaceuticals division of CRA International, a business and litigation consulting firm headquartered in Boston. Kate holds a bachelor’s degree from Bowdoin College in Brunswick, Maine, with a dual major in Economics and Government & Legal Studies.

Product Expertise

• Generic Intelligence & Newport

Publications, Presentations & Conferences

• Interview with Patricia Van Arnum: The Changing Players and Supply Base for Generic Drugs | Pharmaceutical Technology Sourcing and Management | April 6, 2011
• Approaching the patent cliff: how did we get here and what comes nextPDF | DCAT, March 2011
• Interview with Mike Rice: India and China forge ahead while Europe plays catch-up PDF | Generics Bulletin | February 1, 2011
• Downward Trends in Traditional Sourcing Markets and the Rise of Pharmerging Markets | CPhI Virtual Experience Day | October 27, 2010
• Emerging Market API Demand Opportunities PDF | CPhI Spain | Madrid, October 2009
• Opportunities to Sell APIs from Regulated Markets into India and China PDF | SCRIP, May 2009
• Generic Drug Industry Outlook (video) | New York, NY, March 2009
• Identifying Commercial Opportunities to Sell API to Emerging Markets PDF | DCAT Week | New York, March 2009
• The BRIC Countries: Opportunities for Regulated Market Players Pharmaceutical Technology | August 1, 2008
• Emerging Markets as Opportunities, Rather than Threats | DCAT Week | New York, March 2008
• Generic Drugmakers Eye New Opportunities in Japan PDF | Thomson Financial News | April 7, 2008
• Tools and Strategies for Launching a Successful Generic in Today’s Ultra Competitive Environment | European Generic Medicines Congress | Berlin, Germany, September 2007
• Tools and Trends in Generic Product Selection | CPhI China | Shanghai, June 2007
• Responding to the Challenges Facing the Generics Industry PDF | Industrial Pharmacy | September 2006
• Threats and Opportunities for the Generic APIs Industry PDF | SP2 | September 2006
• Threats and Opportunities for the Generic Industry | APIs Europe | Italy, June 2006

Larry Liberti has worked in and with the pharmaceutical industry, in the fields of pharmaceutical and clinical research and development for 30 years. He spent nine years at Wyeth Laboratories in Product Development, Clinical R&D, and Medical Affairs. He served as Editorial Director, North America, for ADIS International before starting Pharmaceutical Information Associates (PIA) a company specializing in regulatory writing and regulatory consulting. He was a co-founder of Astrolabe Analytica under which he helped develop and commercialize the Astrolabe Message Mapping System.

Larry is a pharmacist with a master’s degree in pharmacognosy from the Philadelphia College of Pharmacy and Science. He was awarded the status of Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professional Society in 1996, and in 2000 was made a Fellow of the American Medical Writers Association.

He is an active member of the American Medical Writers Association (AMWA), the Regulatory Affairs Professional Society and the Drug Information Association. He was awarded a fellowship of the AMWA and has published several articles on pharmaceutical marketing.

Product Expertise

• CMR International Institute for Regulatory Science

Presentations & Conferences

• Monitoring the Value of Trial Registration Information | July 16, 2008
• Choosing the Appropriate Medium for Your Publication: Journal Selection Tactics | The International Publication Planning Association (TIPPA) Annual Conference | San Francisco, June 2008
  

Ms. Powell is the Executive Director of Regulatory Strategies for Thomson Reuters. Sarah has 22 years of experience in the pharmaceutical and related regulated industries. For the last 8 years Sarah has worked on a variety of projects related to implementation of regulatory solutions and has contributed to defining product strategies for industry leading software solutions.

While in industry, Sarah performed a variety of roles within the Clinical, Quality, Regulatory Affairs and Regulatory Operations groups. Sarah has extensive experience with preparing regulatory submission for biologic products for submission in the US and EU. She also has detailed knowledge on the requirements for the electronic submissions, including eCTD, and the recently established requirements for electronic submission of labeling information (SPL and PIM).

With over 20 years experience in the industry, Sarah is Chairperson, Regulatory Affairs Special Interest Action Committee, Drug Information Association and a certified member of the Regulatory Affairs Professional Society.

Product Expertise

• Liquent InSight Suite

Presentations & Conferences

• Global Regulatory Strategy Considerations | RAPS Annual Meeting | Boston, September 2008

• Electronic Interactions with the FDA | RAPS Annual Meeting | Baltimore, March 2007
• XML in Pharma – We’ve Done SPL, What’s Next? | DIA EDM Conference |Philadelphia, February 2006

Jane Ricciuti is Director of Regulatory & Pharmaceutical Research and responsible for researching new products and enhancements in the areas of pharmaceutical and biotechnology regulatory affairs. She also writes expert documents for the IDRAC database on all US regulations pertaining to drugs, biologics, and medical devices.

With over 12 years experience in medical writing and over 7 years in regulatory affairs, Jane has published a number of articles in Regulatory Affairs Focus and Medscape Pharmacists. She is a member of the Regulatory Affairs Professional Society, the Drug Information Association and the American Medical Writers Association.

Jane is a graduate of Albany College of Pharmacy, Albany, New York with a Bachelor of Science degree in Pharmacy and Johns Hopkins University, Baltimore, Maryland with a Master of Administrative Science degree in Management.

She has worked previously as a licensed pharmacist in patient care and clinical trials in acute care, oncology, and surgery settings.

Product Expertise

• IDRAC

 

Miriam Bayes joined Thomson Reuters with the acquisition of Prous Science and is now Head of Scientific & Content Development with a team of more than 80 people selecting, analyzing structuring and indexing the content for our databases and on-line clinical platforms as well as producing 5 different journals in the field of Drug R&D. She also acts as project leader of the Biomarkers database.

Her role includes the management of content for Prous Science Integrity, a comprehensive drug discovery and development database providing integrated biological, chemical and pharmacological information to support scientists at the front end of drug research and development.

Miriam graduated as from the Universidad Navarra, was trained in Clinical Pharmacology and obtained her PhD in Medicine from the University of Barcelona where she lectured on clinical pharmacology in pre- and post-graduate programs.

She is a member of European Society of Clinical Pharmacology and has published and presented at congresses on pharmacokinetics, pharmacodynamics and tolerability of drugs in clinical trials.

Product Expertise

• Prous Science Integrity
• BIOMARKERcenter

 

Carolyn Finch is the Biodiscovery Product Specialist responsible for supporting the sales force as they explore the biological information needs of our customers.

Prior to this Carolyn initiated a product knowledge development program for our global sales force where she managed a team of four trainers and provided product knowledge training to employees across the business. The success of the program was recognised with a Gold Award from the Institute of I.T. Training.

Joining us as an editorial patent analyst, Carolyn was responsible for indexing records for DWPI and GENESEQ databases before joining the training and development department where she designed and delivered technical training for our editorial analysts.

She holds a degree in Biology with European Studies from the University of Sussex which included a year in France, working in a Molecular Biology laboratory.

Product Expertise

• BIOMARKERcenter
• BONDplus
• GENESEQ

Colin Williams is the Director of Product Strategy where he is responsible for developing solutions for biologists and those working with this information. Colin has been with us since November 2005, his roles have included editorial operations management and commercial leadership in producing and launching new databases which improve the efficiency of biology based research.

He has a degree in Biochemistry and PhD in X-ray Crystallography entitled “The structure of E. coli Aconitase B” both from the University of Sheffield.

After some brief post doctoral work he moved to ASM Scientific, a start-up biotechnology company in Cambridge, UK. Here, as part of a team of three, he developed a novel isothermal DNA amplification technology for use in point of care pathogen detection winning the 2005 Best Biomedical Research Innovation at the Medical Futures Innovation awards.
Colin has published articles in Nature Structural Biology, Molecular Microbiology and PLoS Biology as well as having a number of granted and published patents and patent applications in the field of DNA amplification.

Product Expertise

• BIOMARKERcenter
• BONDplus
• GENESEQ

Presentations & Conferences

• Sequence Searching | PIUG Biotechnology Conference | 2007 & 2008

Tatiana Nikolskaya, Ph. D., Chief Scientific Officer: Dr. Nikolskaya has 15 years of experience in experimental biology and bioinformatics research at the University of Chicago and at Moscow State University, VNII Genetika, in Russia. Her areas of expertise include genomics, molecular biology, biochemistry, gene therapy, and various aspects of bioinformatics. Dr. Nikolskaya founded GeneGo in 2000 and continues to oversee technology and science development at the company. Dr Nikolskaya holds a Master's degree in Biology from Moscow State University and a Doctoral degree in Molecular Genetics from VNII Genetika Graduate School in Moscow, Russia.

Dr. Nikolsky has over ten years of experience in the life sciences industry, in business and research. Prior to joining GeneGo, he was CEO of ChemDiv (San Diego, CA), a medicinal chemistry outsourcing company. Earlier, he co-founded and served as VP of Business Development at Integrated Genomics, Inc. (Chicago, IL), a comparative genomics and bioinformatics company. Dr. Nikolsky has also held positions as a Senior Scientist for Thermogen, Inc. (Chicago, IL) and as Research Associate (Instructor) at the University of Chicago. Dr. Nikolsky holds an MBA degree in Finance from the University of Chicago, a Master's degree in Biology from Moscow State University, and a Doctoral degree in Molecular Genetics from VNII Genetika Graduate School in Moscow, Russia.

Ann Wescott joined Thomson Reuters with the acquisition of Prous Science in 2007. She has been with Prous Science for more than 20 years and participated in the development of all the company’s drug R&D databases, starting with diskette and classic online formats in the 1980s and progressing to the Prous Science Integrity drug discovery and development online portal.

Product Expertise

• Prous Science Integrity